Clinical segmentation in 22q11.2 deletion syndrome: Cognitive impairments and additional genetic load

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Clinical segmentation in 22q11.2 deletion syndrome : Cognitive impairments and additional genetic load. / Schmock, H.; Stevenson, Matt P.; Hanebaum, S.; Vangkilde, A.; Rosengren, A.; Weinsheimer, S. M.; Skovby, F.; Olesen, C.; Ullum, H.; Baaré, W. F.C.; Siebner, H. R.; Didriksen, M.; Werge, T.; Olsen, L.; Jepsen, J. R.M.

I: Journal of Psychiatric Research, Bind 177, 2024, s. 153-161.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Schmock, H, Stevenson, MP, Hanebaum, S, Vangkilde, A, Rosengren, A, Weinsheimer, SM, Skovby, F, Olesen, C, Ullum, H, Baaré, WFC, Siebner, HR, Didriksen, M, Werge, T, Olsen, L & Jepsen, JRM 2024, 'Clinical segmentation in 22q11.2 deletion syndrome: Cognitive impairments and additional genetic load', Journal of Psychiatric Research, bind 177, s. 153-161. https://doi.org/10.1016/j.jpsychires.2024.06.045

APA

Schmock, H., Stevenson, M. P., Hanebaum, S., Vangkilde, A., Rosengren, A., Weinsheimer, S. M., Skovby, F., Olesen, C., Ullum, H., Baaré, W. F. C., Siebner, H. R., Didriksen, M., Werge, T., Olsen, L., & Jepsen, J. R. M. (2024). Clinical segmentation in 22q11.2 deletion syndrome: Cognitive impairments and additional genetic load. Journal of Psychiatric Research, 177, 153-161. https://doi.org/10.1016/j.jpsychires.2024.06.045

Vancouver

Schmock H, Stevenson MP, Hanebaum S, Vangkilde A, Rosengren A, Weinsheimer SM o.a. Clinical segmentation in 22q11.2 deletion syndrome: Cognitive impairments and additional genetic load. Journal of Psychiatric Research. 2024;177:153-161. https://doi.org/10.1016/j.jpsychires.2024.06.045

Author

Schmock, H. ; Stevenson, Matt P. ; Hanebaum, S. ; Vangkilde, A. ; Rosengren, A. ; Weinsheimer, S. M. ; Skovby, F. ; Olesen, C. ; Ullum, H. ; Baaré, W. F.C. ; Siebner, H. R. ; Didriksen, M. ; Werge, T. ; Olsen, L. ; Jepsen, J. R.M. / Clinical segmentation in 22q11.2 deletion syndrome : Cognitive impairments and additional genetic load. I: Journal of Psychiatric Research. 2024 ; Bind 177. s. 153-161.

Bibtex

@article{e949590bec564bc184d614d24cebf2f1,
title = "Clinical segmentation in 22q11.2 deletion syndrome: Cognitive impairments and additional genetic load",
abstract = "The 22q11.2 deletion syndrome (22q11.2DS) is associated with high psychiatric morbidity. However, large phenotypic heterogeneity hampers early detection of 22q11.2DS individuals at highest risk. Here, we investigated whether individuals with 22q11.2DS can be subdivided into clinically relevant subgroups based on their severity of cognitive impairments and whether such subgroups differ in polygenic risk. Using a cross-sectional design, we examined the number of lifetime psychiatric diagnoses and polygenic risk scores for schizophrenia in an unselected nationwide biobank cohort of individuals with 22q11.2DS (n = 183). Approximately 35% of this sample, aged 10–30 years, had a history with one or more psychiatric diagnosis. In a representative nested subgroup of 28 children and youth, we performed additional comprehensive cognitive evaluation and assessed psychiatric symptoms. Unsupervised hierarchical cluster analysis was performed to divide the subgroup of 22q11.2DS individuals, based on their performance on the cognitive testing battery. This produced two groups that did not differ in mean age or gender composition, but were characterized by low cognitive (LF) and high cognitive (HF) functional levels. The LF group, which had significantly lower global cognitive functioning scores, also displayed higher negative symptom scores; whereas, the HF group displayed lower rate of current psychiatric disorders than the LF group and the reminder of the biobank cohort. The polygenic risk score for schizophrenia was insignificantly lower for the low functioning group than for the high functioning group, after adjustment. Cognitive functioning may provide useful information on psychiatric risk.",
author = "H. Schmock and Stevenson, {Matt P.} and S. Hanebaum and A. Vangkilde and A. Rosengren and Weinsheimer, {S. M.} and F. Skovby and C. Olesen and H. Ullum and Baar{\'e}, {W. F.C.} and Siebner, {H. R.} and M. Didriksen and T. Werge and L. Olsen and Jepsen, {J. R.M.}",
note = "Publisher Copyright: {\textcopyright} 2024 Elsevier Ltd",
year = "2024",
doi = "10.1016/j.jpsychires.2024.06.045",
language = "English",
volume = "177",
pages = "153--161",
journal = "Journal of Psychiatric Research",
issn = "0022-3956",
publisher = "Pergamon Press",

}

RIS

TY - JOUR

T1 - Clinical segmentation in 22q11.2 deletion syndrome

T2 - Cognitive impairments and additional genetic load

AU - Schmock, H.

AU - Stevenson, Matt P.

AU - Hanebaum, S.

AU - Vangkilde, A.

AU - Rosengren, A.

AU - Weinsheimer, S. M.

AU - Skovby, F.

AU - Olesen, C.

AU - Ullum, H.

AU - Baaré, W. F.C.

AU - Siebner, H. R.

AU - Didriksen, M.

AU - Werge, T.

AU - Olsen, L.

AU - Jepsen, J. R.M.

N1 - Publisher Copyright: © 2024 Elsevier Ltd

PY - 2024

Y1 - 2024

N2 - The 22q11.2 deletion syndrome (22q11.2DS) is associated with high psychiatric morbidity. However, large phenotypic heterogeneity hampers early detection of 22q11.2DS individuals at highest risk. Here, we investigated whether individuals with 22q11.2DS can be subdivided into clinically relevant subgroups based on their severity of cognitive impairments and whether such subgroups differ in polygenic risk. Using a cross-sectional design, we examined the number of lifetime psychiatric diagnoses and polygenic risk scores for schizophrenia in an unselected nationwide biobank cohort of individuals with 22q11.2DS (n = 183). Approximately 35% of this sample, aged 10–30 years, had a history with one or more psychiatric diagnosis. In a representative nested subgroup of 28 children and youth, we performed additional comprehensive cognitive evaluation and assessed psychiatric symptoms. Unsupervised hierarchical cluster analysis was performed to divide the subgroup of 22q11.2DS individuals, based on their performance on the cognitive testing battery. This produced two groups that did not differ in mean age or gender composition, but were characterized by low cognitive (LF) and high cognitive (HF) functional levels. The LF group, which had significantly lower global cognitive functioning scores, also displayed higher negative symptom scores; whereas, the HF group displayed lower rate of current psychiatric disorders than the LF group and the reminder of the biobank cohort. The polygenic risk score for schizophrenia was insignificantly lower for the low functioning group than for the high functioning group, after adjustment. Cognitive functioning may provide useful information on psychiatric risk.

AB - The 22q11.2 deletion syndrome (22q11.2DS) is associated with high psychiatric morbidity. However, large phenotypic heterogeneity hampers early detection of 22q11.2DS individuals at highest risk. Here, we investigated whether individuals with 22q11.2DS can be subdivided into clinically relevant subgroups based on their severity of cognitive impairments and whether such subgroups differ in polygenic risk. Using a cross-sectional design, we examined the number of lifetime psychiatric diagnoses and polygenic risk scores for schizophrenia in an unselected nationwide biobank cohort of individuals with 22q11.2DS (n = 183). Approximately 35% of this sample, aged 10–30 years, had a history with one or more psychiatric diagnosis. In a representative nested subgroup of 28 children and youth, we performed additional comprehensive cognitive evaluation and assessed psychiatric symptoms. Unsupervised hierarchical cluster analysis was performed to divide the subgroup of 22q11.2DS individuals, based on their performance on the cognitive testing battery. This produced two groups that did not differ in mean age or gender composition, but were characterized by low cognitive (LF) and high cognitive (HF) functional levels. The LF group, which had significantly lower global cognitive functioning scores, also displayed higher negative symptom scores; whereas, the HF group displayed lower rate of current psychiatric disorders than the LF group and the reminder of the biobank cohort. The polygenic risk score for schizophrenia was insignificantly lower for the low functioning group than for the high functioning group, after adjustment. Cognitive functioning may provide useful information on psychiatric risk.

U2 - 10.1016/j.jpsychires.2024.06.045

DO - 10.1016/j.jpsychires.2024.06.045

M3 - Journal article

C2 - 39018710

AN - SCOPUS:85198535912

VL - 177

SP - 153

EP - 161

JO - Journal of Psychiatric Research

JF - Journal of Psychiatric Research

SN - 0022-3956

ER -

ID: 399062139